Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 2/20 | 0.78 |
| ▸ | CCR3 | P51677 | 2/20 | 0.73 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.64 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.64 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218171 | 0.90 | TMEM97 (0.74) | MCHR1KMT2ADRD4MEN1SIGMAR1 | |
| SCHEMBL6499380 | 0.87 | CCR8 (1.00) | CCR8CCR3SIGMAR1 | |
| SCHEMBL6500103 | 0.85 | CCR8 (1.00) | CCR8SIGMAR1 | |
| SCHEMBL694949 | 0.85 | SIGMAR1 (0.82) | MCHR1KMT2ADRD4MEN1SIGMAR1 | |
| SCHEMBL6509291 | 0.84 | CCR8 (0.82) | CCR8MCHR1SIGMAR1PRKAA2 | |
| SCHEMBL6498271 | 0.84 | CCR8 (0.82) | CCR8CCR3SIGMAR1 | |
| SCHEMBL6499972 | 0.84 | CCR8 (0.73) | CCR8CCR3KMT2ASIGMAR1PRKAA2 | |
| SCHEMBL8738231 | 0.83 | DRD2 (0.77) | MCHR1DRD4 | |
| SCHEMBL8738579 | 0.83 | DRD2 (0.77) | MCHR1DRD4 | |
| SCHEMBL6529983 | 0.82 | CCR8 (0.70) | CCR8CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885CCR3 18/4885MCHR1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.